NCT02056392 - To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions

Solid Tumours

Interventions

DRUG

Selumetinib

Volunteers will receive 75 mg selumetinib oral dose (Treatment A)

DRUG

Moxifloxacin

Volunteers will receive 400 mg Moxifloxacin oral dose (Treatment B)

DRUG

selumetinib placebo

Volunteers will receive selumetinib placebo oral dose (Treatment C)

Trial Locations (1)

Research Site, Overland Park